BR112017004746A2 - métodos para preparação de virossomas adjuvados, para otimizar a proporção adjuvante/antígeno de uma vacina à base de virossoma e para imunizar um indivíduo contra uma doença, virossoma adjuvado, composição farmacêutica, e, composição imunogênica. - Google Patents
métodos para preparação de virossomas adjuvados, para otimizar a proporção adjuvante/antígeno de uma vacina à base de virossoma e para imunizar um indivíduo contra uma doença, virossoma adjuvado, composição farmacêutica, e, composição imunogênica.Info
- Publication number
- BR112017004746A2 BR112017004746A2 BR112017004746A BR112017004746A BR112017004746A2 BR 112017004746 A2 BR112017004746 A2 BR 112017004746A2 BR 112017004746 A BR112017004746 A BR 112017004746A BR 112017004746 A BR112017004746 A BR 112017004746A BR 112017004746 A2 BR112017004746 A2 BR 112017004746A2
- Authority
- BR
- Brazil
- Prior art keywords
- virosome
- adjuvant
- adjuvanted
- virosomes
- preparing
- Prior art date
Links
- 239000000277 virosome Substances 0.000 title abstract 9
- 239000002671 adjuvant Substances 0.000 title abstract 5
- 238000000034 method Methods 0.000 title abstract 3
- 239000000203 mixture Substances 0.000 title abstract 3
- 229960005486 vaccine Drugs 0.000 title abstract 2
- 239000000427 antigen Substances 0.000 title 1
- 102000036639 antigens Human genes 0.000 title 1
- 108091007433 antigens Proteins 0.000 title 1
- 201000010099 disease Diseases 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 1
- 230000003053 immunization Effects 0.000 title 1
- 230000002163 immunogen Effects 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 239000012528 membrane Substances 0.000 abstract 2
- 102000018897 Membrane Fusion Proteins Human genes 0.000 abstract 1
- 108010027796 Membrane Fusion Proteins Proteins 0.000 abstract 1
- 239000003125 aqueous solvent Substances 0.000 abstract 1
- 238000007865 diluting Methods 0.000 abstract 1
- 230000004927 fusion Effects 0.000 abstract 1
- 239000008240 homogeneous mixture Substances 0.000 abstract 1
- 238000003780 insertion Methods 0.000 abstract 1
- 230000037431 insertion Effects 0.000 abstract 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55516—Proteins; Peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
- C12N2760/18523—Virus like particles [VLP]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
- C12N2760/18534—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Virology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Pulmonology (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
a invenção refere-se com os campos da imunologia e vacinologia. é provido um método para a preparação de virossomas adjuvante, compreendendo os etapas de: (i) prover uma composição aquosa de virossomas sem adjuvante compreendendo uma proteína de fusão de membrana; (ii) dissolver um adjuvante anfifílico em um solvente não aquoso farmaceuticamente aceitável que pode formar uma mistura homogénea com água; e (iii) diluir a referida solução adjuvante na referida composição aquosa de virossomas para induzir a inserção de adjuvante no folíolo externo da membrana virossômica enquanto se preserva a atividade de fusão da membrana dos virossomas. são também providos virossomas adjuvados que podem ser obtidos pelo referido método, e vacinas compreendendo os virossomas.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/NL2014/050627 WO2016039619A1 (en) | 2014-09-12 | 2014-09-12 | Methods for providing adjuvanted virosomes and adjuvanted virosomes obtainable thereby |
Publications (2)
Publication Number | Publication Date |
---|---|
BR112017004746A2 true BR112017004746A2 (pt) | 2017-12-05 |
BR112017004746B1 BR112017004746B1 (pt) | 2021-04-06 |
Family
ID=51662289
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112017004746-2A BR112017004746B1 (pt) | 2014-09-12 | 2014-09-12 | Métodos para preparação de virossomas adjuvados e para otimizar a proporção adjuvante/antígeno de uma vacina à base de virossoma, virossoma adjuvado, composição farmacêutica, e, composição imunogênica |
Country Status (12)
Country | Link |
---|---|
US (1) | US10588963B2 (pt) |
EP (1) | EP3191123B1 (pt) |
JP (1) | JP6466571B2 (pt) |
KR (1) | KR102277013B1 (pt) |
CN (1) | CN107073105B (pt) |
AU (1) | AU2014406150B2 (pt) |
BR (1) | BR112017004746B1 (pt) |
CA (1) | CA2960948C (pt) |
ES (1) | ES2807607T3 (pt) |
NZ (1) | NZ730357A (pt) |
RU (1) | RU2694367C2 (pt) |
WO (1) | WO2016039619A1 (pt) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3191123B1 (en) | 2014-09-12 | 2020-06-03 | Bestewil Holding B.v. | Methods for providing adjuvanted virosomes and adjuvanted virosomes obtainable thereby |
CN106243230B (zh) * | 2016-08-26 | 2020-01-17 | 北京岱瑞汛生物科技发展有限公司 | 一种具有霍乱弧菌毒素a亚基和金黄色葡萄球菌特点的人工蛋白及其应用 |
US11523988B2 (en) | 2018-11-29 | 2022-12-13 | Catalent U.K. Swindon Zydis Limited | Oral dispersible vaccine comprising virosomes |
CN110128543A (zh) * | 2019-04-01 | 2019-08-16 | 上海交通大学 | 一种仿病毒囊泡及其制备方法以及其用途 |
US11559577B2 (en) | 2020-03-31 | 2023-01-24 | Engimata, Inc. | Immunogenic composition forming a vaccine, and a method for its manufacture |
US11278617B2 (en) | 2020-03-31 | 2022-03-22 | Engimata, Inc | Immunogenic composition forming a SARS-CoV-2 vaccine, and a method for its manufacture |
CN114989269B (zh) * | 2022-06-30 | 2023-09-19 | 天康制药股份有限公司 | 一种牛赤羽免疫原性抗原及疫苗 |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4542212A (en) | 1975-10-14 | 1985-09-17 | Institut Pasteur | Phosphorylated 3-glyceryl-esters of glucose |
EP0538437B1 (en) | 1991-05-08 | 1999-08-04 | SCHWEIZ. SERUM- & IMPFINSTITUT BERN | Immunostimulating and immunopotentiating reconstituted influenza virosomes and vaccines containing them |
US5936076A (en) | 1991-08-29 | 1999-08-10 | Kirin Beer Kabushiki Kaisha | αgalactosylceramide derivatives |
GB0103170D0 (en) | 2001-02-08 | 2001-03-28 | Smithkline Beecham Biolog | Vaccine composition |
US7592008B2 (en) * | 2000-11-20 | 2009-09-22 | The Board Of Trustees Of The University Of Illinois, A Body Corporate And Politic Of The State Of Illinois | Membrane scaffold proteins |
EP1562550A1 (en) | 2002-11-21 | 2005-08-17 | Pevion Biotech Ltd. | High-efficiency fusogenic vesicles, methods of producing them, and pharmaceutical compositions containing them |
EP1447080A1 (en) | 2003-02-13 | 2004-08-18 | Bestewil Holding B.V. | Method for producing virosome-like particles |
AR056245A1 (es) | 2003-06-19 | 2007-10-03 | Bestewil Holding Bv | Membranas virales reconstituidas funcionales que contienen un coadyuvante |
JP2008500984A (ja) * | 2004-05-28 | 2008-01-17 | グラクソスミスクライン バイオロジカルズ ソシエテ アノニム | ヴィロソームとサポニンアジュバントを含むワクチン組成物 |
EP1652914A1 (en) * | 2004-10-27 | 2006-05-03 | Berna Biotech AG | Virosome particles comprising antigens from influenza virus and Hepatitis B virus |
WO2007099387A1 (en) | 2006-03-03 | 2007-09-07 | Mymetics Corporation | Virosome-like vesicles comprising gp41-derived antigens |
CN102078606B (zh) * | 2010-12-08 | 2014-12-31 | 中国人民解放军军事医学科学院微生物流行病研究所 | 一种呼吸道合胞病毒体疫苗及其制备方法 |
US9241988B2 (en) | 2012-04-12 | 2016-01-26 | Avanti Polar Lipids, Inc. | Disaccharide synthetic lipid compounds and uses thereof |
EP3191123B1 (en) | 2014-09-12 | 2020-06-03 | Bestewil Holding B.v. | Methods for providing adjuvanted virosomes and adjuvanted virosomes obtainable thereby |
-
2014
- 2014-09-12 EP EP14781320.8A patent/EP3191123B1/en active Active
- 2014-09-12 CA CA2960948A patent/CA2960948C/en active Active
- 2014-09-12 WO PCT/NL2014/050627 patent/WO2016039619A1/en active Application Filing
- 2014-09-12 NZ NZ730357A patent/NZ730357A/en unknown
- 2014-09-12 AU AU2014406150A patent/AU2014406150B2/en active Active
- 2014-09-12 US US15/510,578 patent/US10588963B2/en active Active
- 2014-09-12 RU RU2017108644A patent/RU2694367C2/ru active
- 2014-09-12 BR BR112017004746-2A patent/BR112017004746B1/pt active IP Right Grant
- 2014-09-12 JP JP2017514561A patent/JP6466571B2/ja active Active
- 2014-09-12 KR KR1020177009323A patent/KR102277013B1/ko active IP Right Grant
- 2014-09-12 ES ES14781320T patent/ES2807607T3/es active Active
- 2014-09-12 CN CN201480082887.1A patent/CN107073105B/zh active Active
Also Published As
Publication number | Publication date |
---|---|
AU2014406150A1 (en) | 2017-03-30 |
EP3191123B1 (en) | 2020-06-03 |
KR20170063684A (ko) | 2017-06-08 |
RU2694367C2 (ru) | 2019-07-12 |
JP6466571B2 (ja) | 2019-02-06 |
RU2017108644A3 (pt) | 2018-10-12 |
ES2807607T3 (es) | 2021-02-23 |
CN107073105B (zh) | 2021-04-06 |
US10588963B2 (en) | 2020-03-17 |
BR112017004746B1 (pt) | 2021-04-06 |
CA2960948A1 (en) | 2016-03-17 |
KR102277013B1 (ko) | 2021-07-14 |
CA2960948C (en) | 2023-04-04 |
US20170189523A1 (en) | 2017-07-06 |
NZ730357A (en) | 2021-12-24 |
EP3191123A1 (en) | 2017-07-19 |
AU2014406150B2 (en) | 2020-09-10 |
JP2017528484A (ja) | 2017-09-28 |
CN107073105A (zh) | 2017-08-18 |
RU2017108644A (ru) | 2018-10-12 |
WO2016039619A1 (en) | 2016-03-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112017004746A2 (pt) | métodos para preparação de virossomas adjuvados, para otimizar a proporção adjuvante/antígeno de uma vacina à base de virossoma e para imunizar um indivíduo contra uma doença, virossoma adjuvado, composição farmacêutica, e, composição imunogênica. | |
BR112018008102A2 (pt) | vacina de vírus sincicial respiratório | |
MX2022006603A (es) | Vacuna contra el virus de la influenza de amplio espectro. | |
MX2017012220A (es) | Composiciones adyuvantes y metodos relacionados. | |
BR112013022397A2 (pt) | vacinas combinadas com doses menores de antígeno e/ou adjuvante | |
BR112016024644A2 (pt) | vacinas de ácido nucleico | |
BR112018012873A2 (pt) | vacina de vírus zika | |
CO6331297A2 (es) | Composiciones adyuvantes novedosas | |
BR112013017382A2 (pt) | métodos para preparação de glicoesfingolipídios e usos destes | |
BR112016028961A8 (pt) | fibras eletrotorcidas, seu método de preparação e seu uso, bem como composição, e kit | |
AR067087A1 (es) | Composicion de vacuna y metodo para elaborarla | |
EA201391515A1 (ru) | Инактивированная вакцина вируса денге | |
PE20151588A1 (es) | Vacuna contra el virus del dengue | |
EA201490395A1 (ru) | Способ получения фармацевтических композиций, содержащих финголимод | |
MX2017010908A (es) | Vacuna bivalente contra el virus de gripe porcina. | |
CL2016001375A1 (es) | Composición, que comprende agente bioactivo (inmunógeno) dispersado en gotitas de aceite, polímero de recubrimiento entérico, un polímero mucoadhesivo, su método de preparación y uso para la administración oral de un agente bioactivo. | |
CU20180025A7 (es) | Proceso de preparación de una vacuna tetravalente atenuada contra el virus del dengue | |
AR088907A1 (es) | Vacuna | |
ECSP18081582A (es) | Constructos de alfavirus vivo atenuado y métodos y usos de los mismos | |
BR112014031386A2 (pt) | vacinas para meningococos do sorogrupo x | |
AR099960A1 (es) | Procedimientos y composición farmaceutica para inducir una respuesta inmunitaria | |
GT201000066A (es) | Una vacuna multicomponente o monocomponente, para ser utilizada contra la enfermedad de chagas, composiciones farmaceuticas que las contienen, procedimiento para la obtención del inmunógeno de dichas vacunas y acido nucleico utilizado en dicho proced | |
MX2017006744A (es) | Composiciones adyuvantes y metodos relacionados. | |
WO2023104114A3 (en) | Rna formulations and lipids | |
AR102250A1 (es) | Composiciones de vacunas con formación reducida de espuma |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
B15K | Others concerning applications: alteration of classification |
Ipc: A61K 39/12 (2006.01), A61K 39/39 (2006.01), A61K 4 |
|
B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
B09W | Correction of the decision to grant [chapter 9.1.4 patent gazette] |
Free format text: REF. A RPI NO 2597 DE 13/10/2020. |
|
B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 12/09/2014, OBSERVADAS AS CONDICOES LEGAIS. |